Last year Anthropic was known primarily as the safety-focused AI lab founded by ex-OpenAI researchers. Now it's reportedly eyeing an initial public offering at a valuation north of $1 trillion, while simultaneously publishing some of the loudest warnings in the industry about the dangers of unchecked frontier AI development.
The tension is worth naming directly. Anthropic's updated Responsible Scaling Policy lays out concrete commitments about when to pause or constrain model development based on safety evaluations. This is real work - the company employs more safety researchers than nearly any comparable lab and publishes the results. But loud safety advocacy timed alongside pre-IPO momentum creates an obvious uncomfortable dynamic.
The Frontrunner Problem
The structural critique looks like this: if you genuinely believe recursive self-improvement - where models start improving their own capabilities without human direction and spiral beyond human control - could endanger humanity, the rational response isn't to race toward that capability while asking regulators to slow your competitors. Any development pause would disproportionately benefit whoever is already closest to the frontier. Anthropic is very close to the frontier.
This isn't a new critique. OpenAI faced nearly identical questions before its commercial restructuring. But Anthropic's case cuts deeper because its founding story is inseparable from safety - the entire company exists because its founders left OpenAI over disagreements about how carefully powerful AI should be built.
The $1 trillion valuation figure matters beyond optics. At that scale, Anthropic would carry investor expectations that pull toward revenue growth. Safety research doesn't generate revenue. Frontier model deployment does. Anthropic's founders structured it as a public benefit corporation specifically to resist this kind of pressure - but PBC status doesn't make a company immune to it after an IPO.
Two Ways to Read the Same Company
Two interpretations of Anthropic's current position are both defensible. The first: Anthropic genuinely believes it's the least bad actor in a dangerous field, so it presses forward while trying to establish guardrails before others do it worse. The second: safety rhetoric serves regulatory positioning and investor storytelling at a moment when Washington and Wall Street are paying close attention to AI risk.
Both are probably true simultaneously, which is what makes the position hard to evaluate from the outside. The safety community has largely credited Anthropic for publishing detailed evaluation frameworks and committing to measurable thresholds in writing. But that credit has limits when the same company sets the thresholds, evaluates its models against them, and decides whether the bar has been cleared. Independent auditing of those evaluations doesn't exist yet. That structural gap is more consequential than any IPO valuation.